<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531699</url>
  </required_header>
  <id_info>
    <org_study_id>ALT005/09CL/11/06</org_study_id>
    <nct_id>NCT01531699</nct_id>
  </id_info>
  <brief_title>Antimicrobial Efficacy of ALT005 Ophthalmic Prep Solution in Healthy Volunteers</brief_title>
  <official_title>An Open-label Study to Assess the Antimicrobial Efficacy of ALT005 Ophthalmic Prep Solution (ALT005) Compared to Control (Sterile Saline) Following Dermal Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altacor Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altacor Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, single-dose, placebo-controlled efficacy study to assess&#xD;
      the antimicrobial efficacy of ALT005 ophthalmic prep solution following dermal administration&#xD;
      in healthy volunteers. Efficacy will be assessed by comparing the reduction in microbial load&#xD;
      for up to 6 hours to that of saline control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 45 subjects who meet the criteria for inclusion will receive either ALT005 or&#xD;
      control solution (sterile 0.9% saline) on one occasion to sites on the forehead and the&#xD;
      cheeks. Subjects will be randomized in a ratio of 2:1 active:control. Subjects will be dosed&#xD;
      in groups.&#xD;
&#xD;
      The study will run at one study center in the US. Subjects will be housed in the clinical&#xD;
      research facility from the morning of Day -4 until the evening of Day 1. The total duration&#xD;
      of participation for each subject dosed is approximately 21 days (from Day -19 study&#xD;
      orientation through the follow-up call on Day 2, excluding the initial screening period).&#xD;
&#xD;
      In this study, the efficacy of ALT005 will be assessed in healthy volunteers who, after&#xD;
      refraining voluntarily from using topical and oral antimicrobials for at least 2 weeks (14&#xD;
      days), exhibit acceptably high normal flora counts on the designated skin testing sites.&#xD;
&#xD;
      An additional cohort was added (3 ALT005, 6 Comparator Product) to make a non-statistical&#xD;
      comparison of efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3 log10 reduction in microbial load</measure>
    <time_frame>10 minutes post dose</time_frame>
    <description>3 log10 reduction in microbial load at 10 minutes following application to the forehead or cheek compared to Day 1 baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3 log10 reduction in microbial load</measure>
    <time_frame>45 minutes post dose</time_frame>
    <description>3 log10 reduction in microbial load at 45 minutes following application to the forehead or cheek compared to Day 1 baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 log10 reduction in microbial load</measure>
    <time_frame>6 hours post dose</time_frame>
    <description>3 log10 reduction in microbial load at 6 hours following application to the forehead compared to Day 1 baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Infection Secondary to Surgical Procedure</condition>
  <arm_group>
    <arm_group_label>ALT005 Ophthalmic Prep Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>saline control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betadine ophthalmic prep solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALT005 Ophthalmic Prep Solution</intervention_name>
    <description>single application for up to 6 hours</description>
    <arm_group_label>ALT005 Ophthalmic Prep Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline control</intervention_name>
    <description>single application for up to 6 hours</description>
    <arm_group_label>saline control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betadine ophthalmic prep solution</intervention_name>
    <description>single application for up to 6 hours</description>
    <arm_group_label>Comparator Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Medically healthy with no clinically significant findings in the screening results&#xD;
&#xD;
          -  Non-tobacco/nicotine-containing product users&#xD;
&#xD;
          -  Acceptably high normal (&gt;3 log10) flora counts from the designated skin sites on Day&#xD;
             -4.&#xD;
&#xD;
          -  Voluntarily consent to participate in the study.&#xD;
&#xD;
          -  Females reporting spontaneous postmenopausal status&#xD;
&#xD;
          -  WOCBP must either be sexually inactive (abstinent) for 14 days prior to screening and&#xD;
             remain so through 30 days following administration (topical dosing) of the study drug&#xD;
             or have been using acceptable methods of birth control for the times specified&#xD;
&#xD;
          -  WOCBP who have undergone sterilization procedures 6 months prior to Day 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             hematological, gastrointestinal, endocrine, immunologic, dermatologic (including&#xD;
             sensitive skin on the face), neurological, or psychiatric disease, or any other&#xD;
             clinically significant disease not deemed acceptable by the PI.&#xD;
&#xD;
          -  Evidence of compromise to skin integrity of forehead or cheek caused by acute rash,&#xD;
             exacerbation of dermatitis, exacerbation of acne, or any other acute condition deemed&#xD;
             clinically significant by the PI.&#xD;
&#xD;
          -  Tattoo, scar, keloid, or other chronic skin condition located on forehead or cheek&#xD;
&#xD;
          -  Facial hair growth that would interfere with sample collection procedures.&#xD;
&#xD;
          -  Positive urine drug/alcohol or cotinine testing&#xD;
&#xD;
          -  Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg), or hepatitis C antibodies (HCV).&#xD;
&#xD;
          -  History or presence of alcoholism or drug abuse within the 2 years prior to Day 1.&#xD;
&#xD;
          -  Hypersensitivity or idiosyncratic reaction to any ingredients in ALT005.&#xD;
&#xD;
          -  Use of any prescription medication started within 90 days prior to Day 1&#xD;
&#xD;
          -  Use of any over-the-counter (OTC) medication, including herbal products, within the 14&#xD;
             days prior to the Day 1&#xD;
&#xD;
          -  Blood donation or significant blood loss within 56 days prior to Day 1&#xD;
&#xD;
          -  Plasma donation within 7 days prior to Day 1&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days prior to Day 1&#xD;
&#xD;
          -  Females who are pregnant or lactating, or have a positive pregnancy test at screening&#xD;
             or check-in&#xD;
&#xD;
          -  Failure to comply with the pre-treatment restrictions related to showering/washing and&#xD;
             contact with antimicrobial substances.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Connolly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion Inc</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 9, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2012</study_first_posted>
  <disposition_first_submitted>November 2, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>November 4, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 6, 2020</disposition_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

